Add to ORKGSodium-glucose co-transporter type 2 inhibitors belong to modern class of oral hypoglycemic drugs, exerting its effect through the reduction of renal glucose reabsorption. In addition to the hypoglycemic effect, various pleiotropic effects are described for this group of drugs. This article describes the effects of four-week treatment of diabetic rats by sodium-glucose co-transporter type 2 inhibitor dapagliflozin on various metabolic parameters and renal morphofunctional changes. We obtained that the addition of dapagliflozin to insulin-treated rats with streptozotocin-induced diabetes reduced the severity of glomerulosclerosis, and albuminuria
In these studies, Dapagliflozin action was seen in different disease conditions like Diabetes mellit...
Sodium–glucose cotransporter 2 (SGLT2) plays a major role in renal glucose reabsorption. To analyze ...
AbstractThe sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes...
Renal renin-angiotensin system (RAS) activation is one of the important pathogenic mechanisms in the...
Renal renin-angiotensin system (RAS) activation is one of the important pathogenic mechanisms in the...
Diabetes mellitus was originally conceived as a renal disorder. In the last decade, however, there h...
The main goal of both type 1 and type 2 diabetes treatment is reaching long-term and stable glycemic...
AbstractGlucose filtered by kidneys is reabsorbed into the proximal tubule through the sodium-couple...
[[abstract]]The kidney plays an important role in the regulation of plasma glucose. It is estimated ...
Inhibition of glucose transport in the kidney, to produce glucosuria and thus directly lower blood g...
OBJECTIVEdTo examine the effect of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor...
Clinical trials have shown that sodium glucose co-transporter 2 (SGLT2) inhibitors improve clinical ...
OBJECTIVEdTo examine the effect of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor...
Sodium-glucose co-transporter 2 inhibitors are a new class of drug for the treatment of type 2 diabe...
OBJECTIVE — Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insu...
In these studies, Dapagliflozin action was seen in different disease conditions like Diabetes mellit...
Sodium–glucose cotransporter 2 (SGLT2) plays a major role in renal glucose reabsorption. To analyze ...
AbstractThe sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes...
Renal renin-angiotensin system (RAS) activation is one of the important pathogenic mechanisms in the...
Renal renin-angiotensin system (RAS) activation is one of the important pathogenic mechanisms in the...
Diabetes mellitus was originally conceived as a renal disorder. In the last decade, however, there h...
The main goal of both type 1 and type 2 diabetes treatment is reaching long-term and stable glycemic...
AbstractGlucose filtered by kidneys is reabsorbed into the proximal tubule through the sodium-couple...
[[abstract]]The kidney plays an important role in the regulation of plasma glucose. It is estimated ...
Inhibition of glucose transport in the kidney, to produce glucosuria and thus directly lower blood g...
OBJECTIVEdTo examine the effect of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor...
Clinical trials have shown that sodium glucose co-transporter 2 (SGLT2) inhibitors improve clinical ...
OBJECTIVEdTo examine the effect of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor...
Sodium-glucose co-transporter 2 inhibitors are a new class of drug for the treatment of type 2 diabe...
OBJECTIVE — Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insu...
In these studies, Dapagliflozin action was seen in different disease conditions like Diabetes mellit...
Sodium–glucose cotransporter 2 (SGLT2) plays a major role in renal glucose reabsorption. To analyze ...
AbstractThe sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes...